Krishnan Viswanadhan

Dr. Krishnan Viswanadhan joined Agios as Chief Corporate Development and Strategy Officer in March 2025. He is a seasoned biopharmaceutical executive with over 20 years of cross-functional experience in advancing novel medicines for patients with serious and life-threatening diseases.

Prior to joining Agios, Krishnan served as President and Chief Operating Officer at Be Biopharma, where he led all operational aspects of the company. Before that, he was Senior Vice President, Global Cell Therapy Franchise Lead at Bristol Myers Squibb, where he oversaw the integrated cell therapy franchise strategy across the enterprise. In this role, he spearheaded key investments to drive long-term growth and built core capabilities to support the company’s leadership in cell therapy. He also led the teams responsible for the development, approval, and life cycle management of Breyanzi, a CD19 CAR-T therapy, and Abecma, the first BCMA CAR-T therapy. Earlier in his career, Krishnan was Vice President, Business Development and Global Alliances at Celgene Corporation, managing a portfolio of strategic partnerships and equity investments. Before Celgene, he held various roles in regulatory strategy at both large and small biopharmaceutical companies.

Krishnan is a registered pharmacist with a Doctor of Pharmacy degree from Rutgers University and a Master of Business Administration from Cornell University. He currently serves as a non-executive director on the boards of JW Therapeutics, a leading cell therapy company in China and Cargo Therapeutics, a clinical-stage biotechnology company advancing next generation, potentially curative cell therapies for cancer patients.